Prenumeration
STENOCARE announced on May 23rd that the company’s premium product, the Astrum oil, is ready for launch on the Australian market. The product is expected to have several benefits compared to the medical cannabis oil available today, including a higher, more uniform, and faster uptake in the blood. The first product, Astrum 10-10 oil Stenocare, with 10 mg/ml THC and 10 mg/ml CBD, are expected to be available for patients in Australia from the summer of 2024, six months ahead of schedule.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of an comment on STENOCARE. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.